Heart in Diabetes 9th Annual Heart in Diabetes Conference 2025

+ Include: 72 Videos (.mp4) + 72 Audios (.mp3) + 72 Subtitles (.vtt) + 57 PDFs, size: 32.09 GB

+ Target Audience: cardiologists, endocrinologists, and nephrologists

+ Information:

1. Overview

The Heart in Diabetes 9th Annual Conference 2025 provides a comprehensive clinical exploration of the intersection between cardiovascular, renal, and metabolic diseases. The program delivers expert insights into managing resistant hypertension, chronic kidney disease, heart failure, obesity, and dyslipidemia, emphasizing the latest pharmacological advancements such as GLP-1 receptor agonists, SGLT2 inhibitors, and novel lipid-lowering therapies.

Course Date: 2025

2. Learning Objectives

• Evaluate the pathophysiology and clinical management of cardiorenal metabolic diseases, including resistant hypertension and diabetic cardiomyopathy.

• Implement guideline-directed medical therapies using GLP-1 RAs, SGLT2 inhibitors, and novel MRAs to optimize cardio-renal protection in patients with diabetes.

• Analyze the systemic impact of sleep disorders, hypercortisolism, and women-specific risk factors on cardiovascular and metabolic health.

• Assess the latest cardiovascular outcome trials (CVOTs) and integrate emerging lipid-lowering treatments targeting ApoB and CETP into clinical practice.

• Apply digital health technologies, intensive lifestyle interventions, and multidisciplinary approaches to manage complex cases involving obesity and heart failure.

3. Target Audience

Best for cardiologists, endocrinologists, and nephrologists who want updates on cardiorenal metabolic therapies, clinical trials, and obesity.

4. Topics

• Day 1 01 Epidemiology and Pathophysiology of Resistant Hypertension and CKD Treatment

• Day 1 02 Management of Chronic Kidney Disease With or Without Albuminuria

• Day 1 03 Emerging Approaches to the Treatment of Resistant Hypertension

• Day 1 04 Case Presentation – Treatment Resistant Hypertension

• Day 1 05 Cortisol – Impact on Endocrinology & Metabolism

• Day 1 06 Cortisol’s Impact on the Kidney-BP-Bone

• Day 1 07 Cardiovascular Implications of Hypercortisolism

• Day 1 08 Panel Discussion and Q&A – Cortisol & Cardiorenalmetabolic Diseases

• Day 1 09 MASLD and MASH – Pathophysiology, Diagnosis and Management

• Day 1 10 Sleep Health – Implications for Obesity and Diabetes Risk

• Day 1 11 Sleep and Cardiovascular Risk

• Day 1 12 Panel Discussion and Q&A – Sleep Disorders in Cardiometabolism

• Day 1 13 Prediabetes – What’s a Clinician to Do

• Day 1 14 Unraveling the Connection – Diabetes and Dementia

• Day 1 15 Pulmonary Disorders in Diabetes – Implications for Heart Disease

• Day 1 16 Diabetes and Cardiovascular Disease in Older Adults

• Day 1 17 Panel Discussion and Q&A – Diabetes Comorbidities

• Day 1 18 Implementing Guideline-Directed Medical Therapy – Stakeholder-Identified Barriers and Facilitators

• Day 1 19 Population Health Approaches to Accelerate the Prevention of CVD – Moving from Action to Impact

• Day 1 20 Panel Discussion and Q&A – Implementation Science in Practice

• Day 1 21 Dyslipidemia in Women Across a Lifetime Approach to Management

• Day 1 22 Sex Hormones and Anthropometric Measures & Heart Failure Risk in Women

• Day 1 23 Panel Discussion and Q&A – Women’s Health

• Day 1 24 Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone or In Combination With SGLT2 Inhibit…

• Day 1 25 Optimal Strategy for Heart Failure Screening Among Adults With Diabetes Without ASCVD – A Pooled Cohort Analysis

• Day 1 26 Mineralocorticoid Receptor Antagonism Prevents Aortic Plaque Progression and Reduces Left Ventricular Mass and Fibro…

• Day 1 27 Accelerated Risk-Based Implementation of Guideline-Directed Medical Therapy for Chronic Kidney Disease

• Day 1 28 Panel Discussion and Q&A – Circulation

• Day 2 01 Current Trends in Epidemiology of Heart Failure – USA

• Day 2 02 Diabetic Cardiomyopathy – Mechanisms and Future Directions

• Day 2 03 Bromocriptine in the Treatment of Peripartum Cardiomyopathy – Is It Ready for Prime Time

• Day 2 04 Proper Medical Management of HFpEF in 2025

• Day 2 05 Panel Discussion and Q&A – Heart Failure – The Now & The New

• Day 2 06 GLP1-RA, Obesity & Diabetes – Mechanisms of Cardiovascular Protection

• Day 2 07 Cardio-Kidney Protection With Incretin Therapies

• Day 2 08 Incretins – Today and Tomorrow

• Day 2 09 Panel Discussion and Q&A – Current & Future Role of Incretin Therapy

• Day 2 10 Diabetes and Cardiovascular Disease – The Evolution of CV Outcomes Assessment of Antihyperglycemic Medications

• Day 2 11 My Personal Journey to HoFH Diagnosis

• Day 2 12 From Rare to the Very Common – Role of Genetics in Lipid Disorders

• Day 2 13 CETPi – Where Might They Fit Into Clinical Practice

• Day 2 14 Using ApoB in Clinical Practice – From Risk Assessment to Treatment Targets

• Day 2 15 Obesity and Dyslipidemia – Can We Finally Break the Cycle With Dual Agonists

• Day 2 16 The Epidemiology and Pathophysiology of Cardio-Kidney-Metabolic Diseases

• Day 2 17 Unmet Needs in CKD in T1D and Challenges in CKD Beyond Diabetes

• Day 2 18 Finerenone Across the Stages of Heart Failure – From Prevention to Treatment

• Day 2 19 Panel Discussion and Q&A – Cardio-Renal Protection in CKM Diseases

• Day 2 20 Digital Health Technologies for Cardiometabolic Disease & Diabetes

• Day 2 21 Food Is Medicine Strategies for Nutrition Security & Cardiometabolic Health Equity – JACC State-of-the-Art Review

• Day 2 22 Intensive Lifestyle Intervention, Cardiac Biomarkers, and Cardiovascular Outcomes in Diabetes – The Look AHEAD Cardiac…

• Day 2 23 Racial Differences in Diabetic Cardiomyopathy – Results From the Phase 3 Randomized Controlled ARISE-HF Study

• Day 2 24 Panel Discussion and Q&A – JACC

• Day 2 25 Technology in the Management of Diabetes – Addressing Its Role in Comorbidities

• Day 2 26 SGLT2 Inhibitors – Reconsidering, Repurposing, Reimagining

• Day 2 27 Panel Discussion and Q&A – Diabetes Management & Technology

• Day 3 01 Management of Complex Cases – Obesity and Heart Failure

• Day 3 02 The Edema Dilemma – A Case of Diabetes Mellitus, Heart Failure With Preserved Ejection Fraction, Obesity, Chronic Kidne…

• Day 3 03 CRM Management of Complex Cases

• Day 3 04 The Lancet Commission on Obesity

• Day 3 05 Obesity – Role of Medical Management

• Day 3 06 Management of Obesity Addressing Lean Mass Preservation

• Day 3 07 Panel Discussion and Q&A – Obesity

• Day 3 08 Do ACEiARB Still Have a Role in the Era of SGLT2, MRA and GLP1A

• Day 3 09 The Role of Diastolic & Pulse Pressure in CKD & CVD – Management Considerations

• Day 3 10 Aldosterone – The Forgotten Hormone in Hypertension

• Day 3 11 Panel Discussion and Q&A – The Kidney and Hypertension

• Day 3 12 Combination Treatment to Improve Heart and Kidney Outcomes in Diabetic Kidney Disease

• Day 3 13 The Latest Heart Disease & Stroke Statistics – US & Global Data from the American Heart Association

• Day 3 14 Appropriate Cardiac Intervention in the Diabetes Cardiorenal & Metabolic Medicine Patient

• Day 3 15 Serum Lipoproteins & Coronary Atherosclerosis in Asymptomatic U.S. Adults Without Traditional Risk Factors

• Day 3 16 Cardiovascular Outcome Trials Update

• Day 3 17 Panel Discussion and Q&A – ASCVD